154 related articles for article (PubMed ID: 11699410)
1. The serum levels of eosinophil cationic protein (ECP) are related to the infiltration of eosinophils in the tumours of patients with Hodgkin's disease.
Molin D; Glimelius B; Sundström C; Venge P; Enblad G
Leuk Lymphoma; 2001 Jul; 42(3):457-65. PubMed ID: 11699410
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma.
Zanotti R; Trolese A; Ambrosetti A; Nadali G; Visco C; Ricetti MM; Benedetti F; Pizzolo G
Ann Oncol; 2002 Dec; 13(12):1908-14. PubMed ID: 12453859
[TBL] [Abstract][Full Text] [Related]
3. [Our experiences in treating patients with Hodgkin disease in the last decade].
Simon Z; Keresztes K; Miltényi Z; Ress Z; Váróczy L; Vadász G; Gergely L; Illés A
Orv Hetil; 2007 Apr; 148(15):675-82. PubMed ID: 17416575
[TBL] [Abstract][Full Text] [Related]
4. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial.
Hutchinson RJ; Fryer CJ; Davis PC; Nachman J; Krailo MD; O'Brien RT; Collins RD; Whalen T; Reardon D; Trigg ME; Gilchrist GS
J Clin Oncol; 1998 Mar; 16(3):897-906. PubMed ID: 9508171
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
[TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
7. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.
Warzocha K; Bienvenu J; Ribeiro P; Moullet I; Dumontet C; Neidhardt-Berard EM; Coiffier B; Salles G
Br J Cancer; 1998 Jun; 77(12):2357-62. PubMed ID: 9649158
[TBL] [Abstract][Full Text] [Related]
9. Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results.
Comella P; Abate G; Fiore M; Di Finizio G; Frezza P; Scoppa G; Anania C; Coucourde F; Zarrilli D
J Chemother; 1989 Jul; 1(4 Suppl):1254-6. PubMed ID: 16312855
[No Abstract] [Full Text] [Related]
10. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
11. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
12. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data.
Prosnitz LR; Farber LR; Kapp DS; Scott J; Bertino JR; Fischer JJ; Cadman EC
J Clin Oncol; 1988 Apr; 6(4):603-12. PubMed ID: 2451712
[TBL] [Abstract][Full Text] [Related]
13. [Controversial aspects in the current treatment of Hodgkin's disease].
Vicente J
Rev Clin Esp; 1987 Feb; 180(3):158-64. PubMed ID: 2437622
[No Abstract] [Full Text] [Related]
14. [Controversy regarding the treatment of Hodgkin's disease].
Balwierz W; Armata J
Pol Tyg Lek; 1989 Apr; 44(14):315-9. PubMed ID: 2482966
[No Abstract] [Full Text] [Related]
15. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
Weiner MA; Leventhal BG; Marcus R; Brecher M; Ternberg J; Behm FG; Cantor A; Wharam M; Chauvenet A
J Clin Oncol; 1991 Sep; 9(9):1591-8. PubMed ID: 1714950
[TBL] [Abstract][Full Text] [Related]
16. Hodgkin's disease in children: correlation of clinical characteristics, staging procedures, and treatment at the University of Minnesota.
McClain KL; Heise R; Day DL; Lee CK; Woods WG; Aeppli D
Am J Pediatr Hematol Oncol; 1990; 12(2):147-54. PubMed ID: 1696073
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of survival in Hodgkin's lymphoma.
Canellos GP; Niedzwiecki D; Johnson JL
N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568
[No Abstract] [Full Text] [Related]
18. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M
Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060
[TBL] [Abstract][Full Text] [Related]
19. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.
Bartlett NL; Rosenberg SA; Hoppe RT; Hancock SL; Horning SJ
J Clin Oncol; 1995 May; 13(5):1080-8. PubMed ID: 7537796
[TBL] [Abstract][Full Text] [Related]
20. Should MOPP-ABVD alone be standard for childhood Hodgkin's?
Constine LS
J Clin Oncol; 1998 Mar; 16(3):1235. PubMed ID: 9508214
[No Abstract] [Full Text] [Related]
[Next] [New Search]